Azenosertib not checked

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · ZN-c3

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
3 active
12 in total · 7 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Ovarian Cancer, High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer, Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Main trialPhase 3
“This is a randomized, Phase 3 trial designed to evaluate the efficacy and safety of azenosertib compared to Investigator's choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for cyclin E1 protein expression.”In the company’s words, NCT07546500 on ClinicalTrials.gov
Other names
ZN-c3

Other drugs for Ovarian Cancer

All 265 drugs for Ovarian Cancer

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials12

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 31 May 2028 A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Phase 2Recruiting 1 Dec 2026 A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase 1Recruiting 30 Jun 2028 A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
Phase 2Completed 22 Oct 2025 A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma
Phase 1/2Terminated 2 Jul 2024 Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)
Phase 1/2Completed 15 Oct 2025 A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
Phase 1Unknown 30 Jun 2022 A Phase 1b Study of ZN-c3 in Chinese Subjects
Phase 1Completed 30 Aug 2023 A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma
Phase 1Terminated 16 Jul 2024 ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
Phase 1Completed 6 May 2025 A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors
Phase 1/2Ended not given Z0011001-A PHASE 1/2, OPEN-LABEL, MULTI-CENTER STUDY OF ZN-c3 ADMINISTERED IN COMBINATION WITH ENCORAFENIB AND CETUXIMAB IN ADULTS WITH METASTATIC COLORECTAL CANCER
Phase 1Suspended not given PHASE Ib STUDY WITH THE COMBINATION OF LB−100 (PP2A INHIBITOR) AND AZENOSERTIB (WEE1 INHIBITOR) IN PATIENTS WITH METASTATIC COLORECTAL CANCER The COLLEE trial
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Azenosertib

Following is part of Solo: you see every change to Azenosertib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in